Aligos Therapeutics, Inc. (ALGS)
USD 33.01
(-4.24%)
USD 33.01
(-4.24%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -78.99 Million | -79.38 Million | -115.66 Million | -74.26 Million | -46.76 Million | -6.04 Million |
| Net Income | -87.67 Million | -96.04 Million | -128.33 Million | -108.54 Million | -52.26 Million | -13.93 Million |
| Depreciation & Amortization | 3.06 Million | 3.67 Million | 3.77 Million | 3.32 Million | 2.29 Million | 1.29 Million |
| Deferred income taxes | 2.21 Million | - | - | 530 Thousand | - | -110 Thousand |
| Stock-based compensation | 12.65 Million | 14.69 Million | 13.45 Million | 2.97 Million | 752 Thousand | 179 Thousand |
| Change in working capital | -9.52 Million | -1.55 Million | -4.65 Million | 16.06 Million | 3.67 Million | 4.88 Million |
| Other non-cash items | 267 Thousand | -159 Thousand | 86 Thousand | 11.38 Million | -1.22 Million | 1.63 Million |
| Investing Cash Flow | 44.98 Million | -26.29 Million | 3.02 Million | 32.75 Million | 6.79 Million | -69.28 Million |
| Investments in PPE | -19 Thousand | -943 Thousand | -892 Thousand | -2.06 Million | -2.78 Million | -2.51 Million |
| Acquisitions | - | 25.35 Million | -3.91 Million | -34.81 Million | -9.57 Million | - |
| Investment purchases | -11 Thousand | -104.26 Million | -19.08 Million | -45.28 Million | -70.42 Million | -66.77 Million |
| Sales/Maturities of investments | 45.01 Million | 78.91 Million | 23 Million | 80.1 Million | 80 Million | - |
| Other Investing Activities | - | -25.35 Million | 3.91 Million | 34.81 Million | 9.57 Million | -72.84 Million |
| Financing Cash Flow | 88.32 Million | 164 Thousand | 78.67 Million | 192.34 Million | 85.53 Million | 99.88 Million |
| Debt repayment | -96 Thousand | -61 Thousand | -79 Thousand | -58 Thousand | -43 Thousand | -1000.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 88.42 Million | 20 Thousand | 78.58 Million | 155.54 Million | 85.57 Million | 2000.00 |
| Other Financing Activities | 70.98 Million | 205 Thousand | 172 Thousand | 36.86 Million | -43 Thousand | 99.88 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -2.21 Million | 1.72 Million | -313 Thousand | -130 Thousand | 385 Thousand | 2.97 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -7.3 Million | -3.27 Million | -4.33 Million | 16.19 Million | 3.28 Million | 1.9 Million |
| Cash at beginning of period | 81.46 Million | 186.98 Million | 220.94 Million | 70.1 Million | 24.54 Million | - |
| Cash at end of period | 135.77 Million | 81.46 Million | 186.98 Million | 220.94 Million | 70.1 Million | 24.54 Million |
| Capital Expenditure | -19 Thousand | -943 Thousand | -892 Thousand | -2.06 Million | -2.78 Million | -2.51 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 54.31 Million | -105.51 Million | -33.96 Million | 150.84 Million | 45.55 Million | 24.54 Million |
| Free Cash Flow | -79.01 Million | -80.33 Million | -116.55 Million | -76.32 Million | -49.55 Million | -8.56 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 5.06 Million | -34.86 Million | -87.67 Million | -27.89 Million | -18.04 Million | -18.79 Million |
| Depreciation & Amortization | 610 Thousand | 674 Thousand | 3.06 Million | 775 Thousand | 681 Thousand | 769 Thousand |
| Deferred income taxes | - | - | 2.21 Million | -4.55 Million | -15.33 Million | -15.24 Million |
| Stock-based compensation | 2.05 Million | 2.64 Million | 12.65 Million | 2.58 Million | 3.2 Million | 3.19 Million |
| Change in working capital | 4.11 Million | -5.49 Million | -9.52 Million | -293 Thousand | -6.2 Million | 643 Thousand |
| Other non-cash items | -32.03 Million | 17.96 Million | 267 Thousand | 6.72 Million | 15.34 Million | 15.81 Million |
| Investing Cash Flow | 39.99 Million | -88.64 Million | 44.98 Million | -7000.00 | -9000.00 | 25 Million |
| Investments in PPE | -7000.00 | -69 Thousand | -19 Thousand | -7000.00 | -12 Thousand | 7000.00 |
| Acquisitions | - | - | - | - | -7000.00 | 7000.00 |
| Investment purchases | - | -88.57 Million | -11 Thousand | - | -1000.00 | -10 Thousand |
| Sales/Maturities of investments | 40 Million | - | 45.01 Million | - | 11 Thousand | 25 Million |
| Other Investing Activities | - | - | - | - | 3000.00 | 24.99 Million |
| Financing Cash Flow | 281 Thousand | -19 Thousand | 88.32 Million | 87.93 Million | -21 Thousand | 414 Thousand |
| Debt repayment | -16 Thousand | -19 Thousand | -96 Thousand | -4000.00 | -21 Thousand | -47 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 461 Thousand | - | - | -572 Thousand | 111 Thousand | 111 Thousand |
| Common Stock Issuance | 297 Thousand | - | 88.42 Million | 87.94 Million | - | 461 Thousand |
| Other Financing Activities | 297 Thousand | - | 70.98 Million | 71.55 Million | -21 Thousand | 414 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 3.97 Million | 325 Thousand | -2.21 Million | -423 Thousand | -300 Thousand | 419 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 134 Thousand | -5.81 Million | -7.3 Million | 130 Thousand | -5.9 Million | 224 Thousand |
| Cash at beginning of period | 24.36 Million | 135.77 Million | 81.46 Million | 70.5 Million | 90.87 Million | 79.06 Million |
| Cash at end of period | 45.14 Million | 24.36 Million | 135.77 Million | 135.77 Million | 70.5 Million | 90.87 Million |
| Capital Expenditure | -7000.00 | -69 Thousand | -19 Thousand | -7000.00 | -12 Thousand | 7000.00 |
| Effect of forex changes on cash | - | - | - | 21.56 Million | 5.12 Million | -26.69 Million |
| Net cash flow / Change in cash | 20.78 Million | -111.4 Million | 54.31 Million | 65.27 Million | -20.36 Million | 11.8 Million |
| Free Cash Flow | -19.5 Million | -22.81 Million | -79.01 Million | -22.66 Million | -20.34 Million | -13.6 Million |
FORM
UEL
IDX
PARAA
DSX-PB
4095